Antibacterial antifolates: From development through resistance to the next generation

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 8, 2016, Pages

  Estrada, Alexavier ^a   Wright, Dennis L ^a   Anderson, Amy C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAMETHOXAZOLE; TRANSFERASE INHIBITOR; TRIMETHOPRIM; ANTIINFECTIVE AGENT; FOLIC ACID ANTAGONIST;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; GENE MUTATION; KLEBSIELLA PNEUMONIAE; MOLECULAR DYNAMICS; SEQUENCE ALIGNMENT; STAPHYLOCOCCUS AUREUS; TRANSPOSON; DRUG EFFECTS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FOLIC ACID ANTAGONISTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SULFAMETHOXAZOLE; TRIMETHOPRIM RESISTANCE;

EID: 84982835397     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a028324     Document Type: Article

References (34)

1. Amyes S. 1989. The success of plasmid-encoded resistance genes in clinical bacteria. J Med Microbiol 28: 73–83.
2. Amyes S, Towner K, Young H. 1992. Classification of plasmid-encoded dihydrofolate reductases conferring trimethoprim resistance. J Med Microbiol 36: 1–3.
3. Baca A, Sirawaraporn R, Turley S, Sirawaraporn W, Ho W. 2000. Crystal structure of Mycobacterium tuberculosis 6-hydroxymethyl-7,8-dihydropteroate synthase in complex with pterin monophosphate: New insight into the enzymatic mechanism and sulfa-drug action. J Mol Biol 302: 1193–1212.
4. Blahna M, Zalewski C, Reuer J, Kahlmeter G, Foxman B, Marrs C. 2006. The role of horizontal gene transfer in the spread of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli in Europe and Canada. J Antimicrob Chemother 57: 666–672.
5. Brolund A, Sundqvist M, Kahlmeter G, Grape M. 2010. Molecular characterisation of trimethoprim resistance in Escherichia coli and Klebsiella pneumoniae during a two-year intervention on trimethoprim use. PLoS ONE 5: e9233.
6. Dale G, Broger C, Hartman P, Langen H, Page M, Then R, Stuber D. 1995. Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermis ATCC 14990: The origin of the trimethoprim-resistant S1 DHFR from Staphylococcus aureus? J Bacteriol 177: 2965–2970.
7. Dale G, Broger C, D’Arcy A, Hartman P, DeHoogt R, Jolidon S, Kompis I, Labhardt A, Langen H, Locher H, et al. 1997. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J Mol Biol 266: 23–30.
8. Darmstadt G. 1997. Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Pediatr Infect Dis J 16: 227–240.
9. Frei C, Miller M, Lewis J, Lawson K, Hunter J, Oramasionwu C, Talbert R. 2010. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CAMRSA) skin infections. J Am Board Fam Med 23: 714–719.
10. Frey K, Liu J, Lombardo M, Bolstad D, Wright D, Anderson A. 2009. Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternative conformation of NADPH that may be linked to trimethoprim resistance. J Mol Biol 387: 1298–1308.
11. Frey K, Lombardo M, Wright D, Anderson A. 2010. Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase. J Struc Biol 170: 93–97.
12. Frey K, Viswanathan K, Wright D, Anderson A. 2012. Prospectively screening novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance. Antimicrob Agents Chemother 56: 3556–3562.
13. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA; Participants in the CDC-Convened Experts’ Meeting on Management of MRSA in the Community. 2006. Strategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention, www.cdc.gov/mrsa/community/clinicians.
14. Hammoudeh D, Date M, Yun MK, Zhang W, Boyd V, Follis A, Griffith E, Lee R, Bashford D, White S. 2014. Identification and characterization of an allosteric inhibitory site on dihydropteroate synthase. ACS Chem Biol 9: 1294–1302.
15. Hampele I, D’Arcy A, Dale G, Kostrewa D, Nielsen J, Oefner C, Page M, Schonfeld HJ, Stuber D, Then R. 1997. Structure and function of the dihydropteroate synthase from Staphylococcus aureus. J Mol Biol 268: 21–30.
16. Hawser S, Luciuro S, Islam K. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71: 941–948.
17. Heaslet H, Harris M, Fahnoe K, Sarver R, Putz H, Chang J, Subramanyam C, Barreiro G, Miller JR. 2009. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim. Proteins 76: 706–717.
18. Hevener K, Yun MK, Qi J, Kerr I, Baboglu K, Hurdle J, Blakrishna K, Balakrishna K, White S, Lee R. 2012. Structure-based design of novel pyrimidopyridazine derivative as dihydrofolate synthase inhibitors with increased affinity. J Med Chem 53: 166–177.
19. Kaur P, Gautam V, Tewari R. 2015. Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in North India. Microb Drug Resist 21: 380–385.
20. Keshipeddy S, Reeve S, Anderson A, Wright D. 2015. Nonracemic antifolates stereoselectively recruit alternate cofactors and overcome resistance in S. aureus. J Am Chem Soc 137: 8983–8990.
21. Lamb K, Lombardo M, Alverson J, Priestley N, Wright D, Anderson A. 2014. Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyllinked antifolates reveal features for potency and selectivity. Antimicrob Agents Chem 58: 7484–7491.
22. Lombardo M, G-Dayanandan N, Wright D, Anderson A. 2016. Crystal structures of trimethoprim-resistant DfrA1 rationalize potent inhibition by propargyl-linked antifolates. ACS Inf Dis 2: 149–156.
23. Nathwani D, Morgan M, Masterton R, Dryden M, Cookson B, French G, Lewis D; British Society for Antimicrobial Chemotherapy Working Party on Community-Onset MRSA Infections and Infections. 2008. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61: 976–994.
24. Nurjadi D, Olalekan A, Layer F, Shittu A, Alabi A, Ghebremedhin B, Schaumber F, Hofmann-Eifler J, Genderen P, Caumes E, et al. 2014. Emergence of trimethoprim resistance gene dfrG in Staphylococcus aureus causing human infection and colonization in sub-Saharan Africa and its import to Europe. J Antimicrob Chemother 69: 2361–2368.
25. Schneider P, Hawser S, Islam K. 2003. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13: 4217–4221.
26. Sekiguchi J, Tharavichitkul P, Miyoshi-Akiyama T, Chupia V, Fujino T, Araake M, Irie A, Morita K, Kuratsuji T, Kirikae T. 2005. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454). Antimicrob Agents Chemother 49: 3948–3951.
27. Sincak C, Schmidt J. 2009. Iclaprim, a novel diaminopyrimidine for the treatment of resistant Gram-positive infections. Ann Pharmacother 43: 1107–1114.
28. Skold O. 1976. R-factor mediated resistance to sulfonamides by a plasmid-borne, drug-resistant dihydropteroate synthase. Antimicrob Agents Chemother 9: 49–54.
29. Skold O. 2010. Sulfonamides and trimethoprim. Exp Rev Anti Infect Ther 8: 1–6.
30. Stevens D, Bisno A, Chambers H, Everett E, Dellinger P, Goldstein E, Gorbach S, Hirschmann J, Kaplan E, Montoya J, et al. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41: 1373–1406.
31. Then R, Kohl I, Burdeska A. 1992. Frequency and transferability of trimethoprim and sulfonamide resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermis. J Chemother 4: 67–71.
32. van Miert A. 1994. The sulfonamide-diaminopyrimidine story. J Vet Pharmacol 4: 309–316.
33. Yun MK, Wu Y, Li Z, Zhao Y, Waddell MB, Ferreia A, Lee R, Bashford D, White S. 2012. Catalysis and sulfa drug resistance in dihydropteroate synthase. Science 335: 1110–1114.
34. Zhao Y, Hammoudeh D, Yun M, Qi J, White S, Lee R. 2012. Structure-based design of novel pyrimido[4,5-c] pyridazine derivatives as dihydropteroate synthase inhibitors with increased affinity. ChemMedChem 7: 861–870.